Orthopedic Treatment — Non-Surgical Options Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Non-surgical orthopaedic treatment — also called conservative musculoskeletal (MSK) management — encompasses a broad spectrum of evidence-based interventions designed to relieve pain, restore function, and delay or avoid surgery in patients with bone, joint, and soft-tissue conditions. The goal is to optimise the body's intrinsic healing capacity through targeted physiotherapy, external support devices, pharmacological analgesia, interventional injections, and psychological strategies for chronic pain.

Conservative orthopaedic care is delivered by a multidisciplinary team that may include orthopaedic surgeons, physiotherapists, sports medicine physicians, rheumatologists, occupational therapists, orthotists, and clinical psychologists. Treatment is individualised based on the specific diagnosis, severity, functional impairment, patient age, comorbidities, and personal goals.

Current clinical guidelines from NICE, OARSI (2022), and the American Academy of Orthopaedic Surgeons (AAOS) consistently recommend non-surgical approaches as the mandatory first line for the majority of musculoskeletal conditions, reserving surgery for cases where conservative management has failed after an adequate trial — typically three to six months — or where clear surgical indications exist (e.g., cauda equina syndrome, open fractures, complete tendon rupture).

Modern MSK physiotherapy has moved well beyond generic exercise prescription. Evidence-based techniques such as the McKenzie Method for mechanical spinal pain, Maitland joint mobilisation, and Mulligan Sustained Natural Apophyseal Glides (SNAGs) offer clinicians systematic, reproducible approaches with documented outcomes. When combined with judicious use of orthoses, injections, and pain psychology, non-surgical orthopaedic care achieves clinically meaningful improvement in the majority of patients.

This guide provides a detailed, evidence-referenced overview of the full range of non-surgical orthopaedic interventions to help patients and carers understand their options and make informed shared decisions with their healthcare team.

Non-surgical orthopaedic treatment is applicable across a wide range of musculoskeletal diagnoses. The following represent the most common conditions managed conservatively:

• Spinal conditions: Mechanical low back pain, discogenic pain, lumbar spondylosis, cervical radiculopathy, vertebral compression fractures secondary to osteoporosis, and ankylosing spondylitis.
• Degenerative joint disease (osteoarthritis): Knee, hip, shoulder, acromioclavicular, and hand/thumb base OA — the most prevalent indication for conservative MSK care globally.
• Tendinopathies: Rotator cuff tendinopathy, lateral epicondylalgia (tennis elbow), patellar tendinopathy, Achilles mid-portion and insertional tendinopathy, and de Quervain tenosynovitis.
• Ligament injuries: Grade I and II ankle sprains, ACL-deficient knee managed without reconstruction, medial collateral ligament (MCL) injuries.
• Stress fractures: Tibial, metatarsal, and navicular stress fractures requiring protected weight-bearing with walker boot or casting.
• Peripheral nerve conditions: Foot drop managed with ankle-foot orthosis (AFO), carpal tunnel syndrome with wrist splinting, cubital tunnel syndrome.
• Inflammatory arthritis: Rheumatoid arthritis and psoriatic arthritis in conjunction with disease-modifying agents — physiotherapy and orthoses reduce disability and deformity.
• Paediatric orthopaedics: Scoliosis managed with TLSO bracing (Cobb angle 25–45°), clubfoot with serial casting (Ponseti method), Legg-Calvé-Perthes disease.
• Chronic widespread pain: Fibromyalgia and central sensitisation managed with interdisciplinary pain programmes, CBT, graded exercise, and duloxetine.

The vast majority of patients presenting with musculoskeletal complaints are appropriate candidates for non-surgical orthopaedic management as first-line care. Eligibility assessment focuses on identifying the right combination of modalities and ensuring specific contraindications are respected for individual interventions.

General eligibility criteria:

• Musculoskeletal diagnosis confirmed by clinical examination, with or without imaging support
• Absence of surgical emergencies or red flags (cauda equina syndrome, spinal cord compression, open fracture, septic arthritis, acute compartment syndrome)
• Patient preference for non-operative management and ability to engage with prescribed programme
• Adequate functional reserve to participate in physiotherapy or exercise-based rehabilitation

Modality-specific contraindications:

• Corticosteroid injections: Active local infection, poorly controlled diabetes mellitus (transient hyperglycaemia post-injection), anticoagulation therapy (relative), allergy to corticosteroid or anaesthetic agent. Repeated injections into weight-bearing joints (more than three per year) may accelerate cartilage loss.
• NSAIDs: Active peptic ulceration, eGFR <30 mL/min, established cardiovascular disease (selective COX-2 inhibitors increase cardiovascular risk). Gastroprotection with a proton pump inhibitor (PPI) is mandated for patients over 65 years or with additional GI risk factors.
• PRP injections: Active infection, haematological malignancy, platelet dysfunction, or use of antiplatelet/anticoagulant medication within the recommended washout period.
• Casting and bracing: Open wounds or active skin infection at the site, vascular compromise, severe oedema, or known allergy to casting materials.
• Physiotherapy mobilisation: Undiagnosed inflammatory arthritis with acute flare, fracture not yet consolidated, and certain high-velocity spinal manipulation techniques are contraindicated in osteoporosis or vascular anomalies.

Surgical referral is indicated when: (1) conservative management has been optimised for an adequate trial period (typically 3–6 months for soft-tissue conditions, shorter for fractures with displacement); (2) neurological deficit is progressive; (3) quality of life impact is severe; or (4) imaging demonstrates structural pathology unsuitable for conservative care.

1. Physiotherapy and Manual Therapy

Physiotherapy is the cornerstone of conservative MSK care. The McKenzie Method (MDT) classifies mechanical spinal pain into directional preference categories and prescribes specific movements to centralise and abolish symptoms — supported by multiple RCTs for acute and chronic back pain. Maitland joint mobilisation (Grades I–IV oscillatory techniques) is widely used for peripheral joint stiffness and pain in conditions such as shoulder impingement, ankle stiffness post-fracture, and cervical spondylosis. Mulligan Sustained Natural Apophyseal Glides (SNAGs) combine passive joint mobilisation with active patient movement and demonstrate rapid pain-free range of motion improvements in cervical and lumbar pain. Exercise therapy — aerobic conditioning plus targeted strengthening — is the single most evidence-backed intervention for OA and chronic spinal pain across all guidelines.

2. Bracing and Immobilisation

A walker boot (CAM boot) provides controlled ankle motion and protected weight-bearing for ankle fractures, Jones fractures, and tibial stress fractures. The TLSO (Thoracolumbar Spinal Orthosis) is prescribed for vertebral compression fractures, reducing pain and kyphosis progression; in adolescent idiopathic scoliosis (AIS), high-compliance TLSO bracing significantly reduces curve progression requiring surgery (BrAIST trial). The DonJoy ACL functional brace stabilises the ACL-deficient knee during sport or heavy manual work, enabling non-operative management in selected patients.

3. Casting

Below-knee (short leg) plaster or fibreglass casts immobilise the ankle and foot for fractures, acute ligament injuries, and the Ponseti correction of clubfoot. Above-knee (long leg) casts are reserved for tibial shaft fractures and some knee injuries requiring complete immobilisation. Waterproof fibreglass casts improve hygiene and patient comfort compared with plaster of Paris but offer less moulding precision in fresh injuries.

4. Orthoses

An ankle-foot orthosis (AFO) corrects foot drop by maintaining the ankle in neutral dorsiflexion, enabling safe ambulation in patients with common peroneal nerve palsy or stroke-related weakness. Knee unloading braces (e.g., Unloader One) redistribute medial compartment load in unicompartmental knee OA, reducing pain by 2–3 points on VAS. Custom insoles address pes planus, plantar fasciitis, and forefoot pain.

5. Injections

Corticosteroid injections (e.g., methylprednisolone 40 mg + lidocaine) provide clinically meaningful short-term pain relief of 2–6 weeks per Cochrane meta-analysis, but benefits are not sustained beyond 12 weeks. PRP (Platelet-Rich Plasma) injections contain autologous growth factors; the RESTORE trial (NEJM Evidence, 2021) — the largest high-quality RCT — found PRP not superior to hyaluronic acid for knee OA. Hyaluronic acid (viscosupplementation) is not recommended by NICE UK for knee OA due to marginal clinical benefit; however, it remains used in many countries. Prolotherapy (dextrose sclerosant injection into ligament entheses) has emerging evidence for knee OA and low back pain but is not mainstream.

6. Pharmacological Management

Topical NSAIDs (diclofenac gel 1%) are recommended as the first pharmacological step for knee and hand OA (NICE 2022, OARSI 2022), offering local efficacy with minimal systemic absorption. Oral NSAIDs provide short-term pain relief but require GI protection. Duloxetine (SNRI, 60–120 mg daily) is now supported by multiple RCTs and meta-analyses for chronic MSK pain and knee OA, with a number-needed-to-treat (NNT) of approximately 10 for 50% pain reduction. Paracetamol has limited efficacy for OA per Cochrane 2016. Bisphosphonates form the pharmacological backbone for osteoporosis-related fracture prevention (see osteoporosis treatment guide).

7. Pain Psychology and Interdisciplinary Management

Cognitive Behavioural Therapy (CBT) targets pain catastrophising, fear-avoidance beliefs, and activity avoidance central to chronic MSK pain — Cochrane systematic review (2021) demonstrates 20–30% pain and disability reduction versus controls. Acceptance and Commitment Therapy (ACT) and pain neuroscience education (PNE) complement physical rehabilitation. Interdisciplinary pain management programmes combining medical, physiotherapy, and psychological input achieve superior outcomes to unimodal treatment in chronic widespread MSK pain.

Non-surgical orthopaedic care offers substantial advantages as a first-line management strategy:

• Avoidance of surgical risk: Eliminates exposure to anaesthetic complications, surgical site infection (SSI rates of 0.5–2% for elective orthopaedic procedures), deep vein thrombosis, blood loss, and implant-related issues.
• No hospital admission: The majority of conservative interventions — physiotherapy, bracing, orthoses, injections — are delivered in outpatient or community settings, reducing cost and logistical burden on patients and healthcare systems.
• Reversibility and adaptability: Conservative treatments can be modified, escalated, or de-escalated based on clinical response; they do not close the door to future surgical intervention should it become necessary.
• Addresses biomechanical root causes: Skilled physiotherapy identifies and corrects movement dysfunction, muscle imbalance, and postural habits that perpetuate injury cycles, reducing recurrence rates compared with symptomatic treatment alone.
• Cost-effectiveness: For conditions such as uncomplicated low back pain and early-to-moderate knee OA, conservative management costs substantially less than surgery, with comparable long-term patient-reported outcomes in appropriately selected cases.
• Comorbidity-friendly: Many patients with significant cardiac, renal, or pulmonary comorbidities who are high-risk surgical candidates can achieve meaningful quality-of-life improvement through optimised conservative care.
• Mental health benefits: Exercise-based rehabilitation has well-established antidepressant and anxiolytic effects, and CBT directly targets the psychological component of chronic pain, improving mood, sleep, and social participation.
• Evidence base: Multiple Cochrane systematic reviews, NICE guidelines, and high-quality RCTs underpin the majority of conservative orthopaedic interventions, ensuring treatments recommended are grounded in robust science.

While generally safer than surgery, non-surgical orthopaedic interventions carry specific risks that patients should understand:

Corticosteroid injections: Local infection (rare, 1 in 14,000–50,000), skin depigmentation and subcutaneous fat atrophy at injection site, transient hyperglycaemia in diabetic patients (blood glucose monitoring advised for 24–48 hours post-injection), and theoretical risk of cartilage damage with repeated intra-articular use. Tendon rupture risk with peri-tendinous injection into weight-bearing tendons such as the Achilles — intra-tendinous injection is generally avoided.

NSAID medications: Gastrointestinal irritation, peptic ulceration, and upper GI bleeding — risk significantly mitigated by co-prescribing a PPI. Fluid retention and blood pressure elevation with chronic use. Worsening renal function in patients with pre-existing chronic kidney disease. Increased cardiovascular events with long-term use of both non-selective NSAIDs and COX-2 inhibitors (diclofenac has the highest cardiovascular risk among common NSAIDs).

Bracing and casting: Pressure sores, skin maceration, and contact dermatitis from cast or brace materials. Muscle atrophy and joint stiffness with prolonged immobilisation. Deep vein thrombosis (DVT) — particularly with above-knee casts immobilising the calf muscle pump; thromboprophylaxis should be considered per local guidelines. Compartment syndrome can be masked by a tight cast and requires immediate assessment if pain escalates.

PRP injections: Transient pain flare lasting 24–72 hours post-injection is common. Infection risk (low, similar to any injection procedure). Variable outcomes — RESTORE trial demonstrated no superiority over HA, raising questions about cost-effectiveness at £500–£1,500 per injection in private practice.

Physiotherapy and manual therapy: High-velocity spinal manipulation (HVLA) carries a very low but non-negligible risk of adverse events, including vertebral artery dissection with cervical manipulation (estimated 1 in 400,000–3,000,000 procedures). HVLA is contraindicated in osteoporosis, fracture, and known vertebral artery disease. Delayed onset muscle soreness (DOMS) is expected with new exercise programmes and is not a sign of harm.

Orthoses: Dependency — prolonged AFO use may reduce motor recovery in post-stroke patients; functional electrical stimulation (FES) is preferred when neurological recovery is the primary goal. Ill-fitting orthoses can cause pressure ulcers, particularly in patients with peripheral neuropathy or poor skin integrity.

Regular follow-up is essential to evaluate treatment response, identify complications, and adjust the management plan. Specific follow-up protocols vary by intervention:

Physiotherapy: Initial reassessment after 4–6 treatment sessions (approximately 4–6 weeks). Outcome measures such as the Visual Analogue Scale (VAS) for pain, PSFS (Patient-Specific Functional Scale), and condition-specific questionnaires (KOOS for knee, NDI for neck, DASH for upper limb) are recorded at baseline and repeated at review. Failure to achieve at least 30% improvement in pain or function after eight to twelve sessions should prompt diagnostic reconsideration and possible surgical referral.

Fractures in cast or brace: Repeat plain X-rays at 1–2 weeks after initial application to confirm fracture alignment, particularly for unstable fractures. Final imaging on cast removal to confirm consolidation. Physiotherapy rehabilitation commences promptly after cast removal to restore range of motion and strength.

Orthopaedic injections: Review at 6–8 weeks post-injection to assess response. If corticosteroid injection provides significant but temporary benefit, a second injection may be offered; a maximum of three injections per joint per year is generally recommended. Lack of response should prompt reassessment of diagnosis and consideration of alternative modalities or surgical referral.

NSAID and duloxetine therapy: Renal function (U&E), blood pressure, and GI symptoms should be reviewed at 3 months for patients commenced on long-term oral NSAIDs. Duloxetine is titrated from 30 mg to 60 mg daily at two weeks; full efficacy is assessed at 8–12 weeks. Liver function monitoring is recommended for patients on duloxetine with pre-existing hepatic conditions.

Bracing for scoliosis or OA: Compliance monitoring is essential for TLSO bracing in AIS — brace wear of 18+ hours per day is required to demonstrate efficacy. Knee unloading braces should be reassessed every 6 months for fit, wear, and clinical benefit.

Pain psychology and interdisciplinary programmes: Progress is reviewed using validated psychological outcome tools (e.g., PCS — Pain Catastrophising Scale, PSEQ — Pain Self-Efficacy Questionnaire) at programme completion and at 6-month follow-up.

The cost of non-surgical orthopaedic care varies significantly depending on the specific intervention, country of treatment, provider setting (public vs private), and duration of management required. The following provides indicative ranges for international patients:

Physiotherapy: Individual physiotherapy sessions typically cost USD 40–120 per session in Western countries, with packages of 6–12 sessions commonly required. In India, Thailand, and other medical tourism destinations, costs are 50–70% lower. NHS (UK) and Medicare/Medicaid (USA) cover physiotherapy with varying referral criteria.

Custom orthoses: Off-the-shelf braces (DonJoy, Unloader One) range from USD 200–700. Custom-moulded ankle-foot orthoses (AFOs) from a certified orthotist cost USD 400–1,200 depending on complexity. Custom insoles (foot orthoses) from a podiatrist or orthotist: USD 200–600.

Injections: Corticosteroid injections under ultrasound guidance cost approximately USD 150–500 in the USA, and USD 50–200 in India, Thailand, or Mexico. PRP injections range from USD 500–2,000 per injection in private practice globally, and are rarely covered by insurance given inconclusive efficacy evidence. Prolotherapy sessions: USD 150–500 per session.

Medications: Topical diclofenac gel and generic oral NSAIDs are inexpensive and widely available (USD 5–30/month). Duloxetine generic formulations have reduced costs significantly; branded preparations vary. Specialist-prescribed biologics for inflammatory arthritis add substantially to costs (USD 15,000–30,000 per year).

Pain psychology: CBT sessions from a clinical psychologist: USD 100–250 per session; 6–12 sessions typically recommended. Interdisciplinary pain management programmes: USD 3,000–10,000 for a 3–4 week residential or intensive day programme.

Insurance coverage: Physiotherapy, casting, and bracing for fractures are typically covered by insurance. Regenerative injections (PRP, prolotherapy) are usually classified as experimental and excluded from most policies. Travel medical insurance should be verified for all treatments undertaken abroad.

When non-surgical orthopaedic treatment does not achieve adequate symptom control or functional restoration after an appropriate trial, or when specific structural pathology mandates operative intervention, the following alternatives are considered:

Surgical orthopaedic procedures:

• Total knee arthroplasty (TKA) and total hip arthroplasty (THA): Gold-standard surgery for end-stage hip and knee OA. NICE recommends referral when symptoms and functional limitation are severe and the patient is suitable for surgery (NICE TA304/TA395 criteria). Implant survival exceeds 90% at 15 years in registry data.
• Unicompartmental knee arthroplasty (UKA): Medial compartment resurfacing for unicompartmental disease; faster recovery than TKA but revision rates slightly higher at 10 years.
• Spinal fusion and discectomy: For persistent radiculopathy from disc herniation unresponsive to 6 weeks of conservative care, or for spinal stenosis causing neurogenic claudication.
• ACL reconstruction: Indicated for young active patients with ACL rupture who fail functional rehabilitation, or with associated meniscal or cartilage injury.
• Fracture fixation: Open reduction and internal fixation (ORIF) or intramedullary nailing for displaced fractures, fractures with vascular compromise, or failed conservative fracture management.

Complementary and alternative approaches:

• Acupuncture: NICE recommends acupuncture as an option for chronic primary pain (NG193); evidence for specific orthopaedic diagnoses is mixed. May offer benefit as an adjunct to physiotherapy for chronic neck and low back pain.
• Bariatric surgery: Weight loss of ≥10% body weight significantly reduces knee OA symptoms and functional limitation; in patients with morbid obesity, bariatric surgery may achieve sustained weight loss that reduces orthopaedic surgical risk and knee joint load.
• Hydrotherapy and balneotherapy: May provide pain relief and functional improvement in patients who cannot tolerate land-based exercise, particularly in inflammatory arthritis and fibromyalgia.